Compare YSXT & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | ALLR |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | China | United States |
| Employees | 38 | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 25.6M |
| IPO Year | N/A | 2021 |
| Metric | YSXT | ALLR |
|---|---|---|
| Price | $0.94 | $1.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | ★ 156.4K | 86.9K |
| Earning Date | 02-03-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.77 |
| 52 Week High | $5.01 | $2.35 |
| Indicator | YSXT | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 49.15 |
| Support Level | $0.75 | $1.01 |
| Resistance Level | $1.28 | $1.28 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 60.92 | 67.84 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services, and Software Development and Information Technology Services. Key revenue is generated from the Auto Insurance Aftermarket Value-added Services segment, which includes four types of value-added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services, and vehicle maintenance and other value-added services.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.